Haemonetics Names Chan Chief Operating Officer

Dow Jones
03-04

By Emon Reiser

Haemonetics appointed Dr. Frank Chan, a longtime Medtronic executive, as vice president and chief operating officer, effective April 7.

The Boston-based blood collection and transfusion services company on Monday said Chan has more than 25 years of experience in the medical device and healthcare technology sectors. He was recently president of acute care and monitoring at Medtronic, where he has held leadership positions since 2015. Chan will report to Haemonetics Chief Executive Officer Chris Simon.

Haemonetics also promoted Roy Galvin, currently president of the company's global plasma and blood center, to chief commercial officer, effective immediately. His expanded role gives him responsibility over the company's global hospital business, and its global plasma and blood center business. Stewart Strong will continue in his role as president of global hospital for Haemonetics until April 1, and then transition to become an adviser to the CEO for a temporary period.

Write to Emon Reiser at emon.reiser@wsj.com

 

(END) Dow Jones Newswires

March 03, 2025 18:01 ET (23:01 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10